Clinical Trial News and Research

RSS

ChemGenex shares falter as FDA requests more data on new leukemia drug

ChemGenex Pharmaceuticals Ltd. Shares fell most in the last 16 years to AUD$0.44 following a concern raised by the US drug regulators – US FDA. The FDA requested on Monday for more uniform clinical test data before they review and consider approval of the company’s new leukemia drug.

23 Mar 2010

Ipsen, GTx expand partnership for toremifene 80 mg

Ipsen today announced the expansion of their partnership for the development and commercialization of toremifene 80 mg for the reduction of fractures in men with advanced prostate cancer on androgen deprivation therapy (ADT) and toremifene 20 mg for the prevention of prostate cancer in high risk patients with High Grade Prostatic Intraepithelial Neoplasia lesions (HGPIN).

23 Mar 2010

FDA's ODAC voted to review T315I mutation prior to approval of OMAPRO

ChemGenex Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee voted 7-1 that a validated test to identify the T315I mutation should be reviewed by the FDA prior to approval of OMAPRO™ (omacetaxine mepesuccinate).

23 Mar 2010

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Can-Fite BioPharma Ltd, a biopharmaceutical company, traded on the TASE and developing anti- inflammatory and anti-cancer drugs, announced today the filing of a patent application, in conjunction with the United Stated National Institutes of Health (NIH), for the treatment of Uveitis with its A3 adenosine receptor ligands.

23 Mar 2010

$CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval$

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

Cell Therapeutics, Inc. announced today that the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee panel voted unanimously that clinical trial data was not adequate to support approval of pixantrone for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

23 Mar 2010

Advaxis' ADXS11-001 Phase 1 study for cervix cancer failures: 13.3% of treated patients alive at over 3 years

Ongoing follow up of the surviving patients from the phase I study of ADXS11-001 for the treatment of cervix cancer failures conducted by Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has shown that two of fifteen treated patients or 13.3% are still alive 1,248 and 1,128 days after receiving their initial dose.

23 Mar 2010

GSK notifies regulatory authorities of the presence of PCV-1 in Rotarix vaccine

GlaxoSmithKline today confirmed that it has notified regulatory authorities of the presence of material from a virus called PCV-1 in its oral rotavirus vaccine, Rotarix™. PCV-1 does not multiply in humans and is not known to cause illness in humans.

23 Mar 2010

Patient dosing in CyDex Pharmaceuticals' Phase 2A clinical trial of CDX-353 initiated

CyDex Pharmaceuticals, Inc. today announced the initiation of patient dosing in the company’s Phase 2A clinical trial of its Captisol-Enabled® Melphalan HCL. Melphalan is an FDA-approved chemotherapy for the palliative treatment of multiple myeloma marketed under the brand name Alkeran® by GlaxoSmithKline.

22 Mar 2010

Pevion Biotech commences Phase 1 clinical trial of PEV7 vaccine

Pevion Biotech, the Swiss vaccine company, today announced that PEV7, the first vaccine for chronic recurrent thrush - recurrent vulvovaginal candidiasis has entered Phase 1 clinical trial.

22 Mar 2010

ChemoCentryx undertakes Phase II clinical trial of CCX140

ChemoCentryx, Inc., today announced that it has undertaken a Phase II clinical trial of CCX140, a novel, orally-available small molecule compound designed to specifically target the chemokine receptor known as CCR2.

22 Mar 2010

Investment report on Gentium from InvestorSoup.com

InvestorSoup.com announces an investment report featuring Gentium SpA. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

22 Mar 2010

StockPreacher.com releases investment report on A.P. Pharma

StockPreacher.com announces an investment report featuring A.P. Pharma Inc. (Nasdaq:APPA). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

22 Mar 2010

Calando Pharmaceuticals demonstrates first targeted siRNA-containing nanoparticle delivery to tumors

Arrowhead Research Corporation today announced that the clinical trial being conducted by majority-owned subsidiary, Calando Pharmaceuticals, Inc., has demonstrated systemic delivery of siRNA and the successful “silencing” of a widely recognized cancer gene via RNA interference (RNAi) in humans.

22 Mar 2010

Vical awarded contract to conduct Phase 1 clinical trial of Vaxfectin-formulated DNA vaccine against A/H1N1

Vical Incorporated announced today that the U.S. Navy, through the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., has awarded Vical a contract to conduct a Phase 1 clinical trial of the company's Vaxfectin®-formulated DNA vaccine against A/H1N1 pandemic influenza (swine flu).

22 Mar 2010

FDA convenes Advisory Committee meeting to discuss safety of LABA's

On Wednesday, March 10 and Thursday, March 11, the FDA is convening an Advisory Committee meeting on the clinical trial design for long acting beta-2 adrenergic agonists.

22 Mar 2010

Nanotechnology weapons for cancer

US Researchers have come up with new nanoparticle robots that are essentially a tiny army that can travel in the blood till they reach the cancers and then tweak some important cancer causing genes that can cure the cancer.

22 Mar 2010

Caltech-led trial demonstrates feasibility of nanoparticles and RNAi-based therapeutics for treating cancer

A California Institute of Technology -led team of researchers and clinicians has published the first proof that a targeted nanoparticle-used as an experimental therapeutic and injected directly into a patient's bloodstream-can traffic into tumors, deliver double-stranded small interfering RNAs (siRNAs), and turn off an important cancer gene using a mechanism known as RNA interference (RNAi).

22 Mar 2010

Sorin Group reports consolidated revenues of € 689.0M for 2009

“The final 2009 financial statements confirm the full achievement of our targets; this solid financial basis will be the foundation for future growth. The 2010-2014 Plan confirms the strategic guidelines previously communicated, based on profitability and cash flow expansion and prepares for accelerated growth in the future” said André-Michel Ballester, Chief Executive Officer, Sorin Group.

20 Mar 2010

Cedars-Sinai Neurovascular Center's clinical trial of minimally invasive stenting procedure for TIA

Individuals between 30 and 80 years of age, who have had a transient ischemic attack (TIA) or non-severe stroke within the past 30 days, and who cannot be treated surgically, may be eligible to participate in a Phase III clinical trial of a minimally invasive stenting procedure at the Cedars-Sinai Neurovascular Center. The study will focus specifically on patients who have had an intracranial artery narrowed by at least 70 percent and who are experiencing recurrent strokes or TIAs despite being on anti-clotting medication.

19 Mar 2010

CPEX Pharmaceuticals' Phase 2a Nasulin trial fails, Arcadia Capital Advisors issues statement

Richard S. Rofe, who serves as Managing Director for Arcadia Capital Advisors, LLC, and is part of a shareholder group that includes Arcadia with a 9.97 percent ownership interest in CPEX Pharmaceuticals, Inc.,, commented on CPEX's recent announcement of failed Phase 2a Nasulin study results.

19 Mar 2010

Clinical Trial News and Research

ChemGenex shares falter as FDA requests more data on new leukemia drug

Ipsen, GTx expand partnership for toremifene 80 mg

FDA's ODAC voted to review T315I mutation prior to approval of OMAPRO

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

Advaxis' ADXS11-001 Phase 1 study for cervix cancer failures: 13.3% of treated patients alive at over 3 years

GSK notifies regulatory authorities of the presence of PCV-1 in Rotarix vaccine

Patient dosing in CyDex Pharmaceuticals' Phase 2A clinical trial of CDX-353 initiated

Pevion Biotech commences Phase 1 clinical trial of PEV7 vaccine

ChemoCentryx undertakes Phase II clinical trial of CCX140

Investment report on Gentium from InvestorSoup.com

StockPreacher.com releases investment report on A.P. Pharma

Calando Pharmaceuticals demonstrates first targeted siRNA-containing nanoparticle delivery to tumors

Vical awarded contract to conduct Phase 1 clinical trial of Vaxfectin-formulated DNA vaccine against A/H1N1

FDA convenes Advisory Committee meeting to discuss safety of LABA's

Nanotechnology weapons for cancer

Caltech-led trial demonstrates feasibility of nanoparticles and RNAi-based therapeutics for treating cancer

Sorin Group reports consolidated revenues of € 689.0M for 2009

Cedars-Sinai Neurovascular Center's clinical trial of minimally invasive stenting procedure for TIA

CPEX Pharmaceuticals' Phase 2a Nasulin trial fails, Arcadia Capital Advisors issues statement

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News